An introduction to chimeric antigen receptor (CAR) T‐cell immunotherapy for human cancerSteven Feins, Joseph A. Fraietta|American Journal of Hematology|2019Cited by 608
T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapyGuido Ghilardi, Marco Ruella, Joseph A. Fraietta et al.|Nature Medicine|2024Cited by 254
FOXO1 is a master regulator of memory programming in CAR T cellsAlexander Doan, Evan W. Weber, Katherine P. Mueller et al.|Nature|2024Cited by 189
Deletion of the inhibitory co-receptor CTLA-4 enhances and invigorates chimeric antigen receptor T cellsSangya Agarwal, Carl H. June, M. Ángela Aznar et al.|Immunity|2023Cited by 164
BLIMP1 and NR4A3 transcription factors reciprocally regulate antitumor CAR T cell stemness and exhaustionIn-Young Jung, Joseph A. Fraietta|Science Translational Medicine|2022Cited by 126